CSP #2018 - Growth Hormone Replacement Therapy in Veterans With Mild Traumatic Brain Injury (mTBI) and Adult Growth Hormone Deficiency (AGHD)
The purpose of this study is to determine whether growth hormone replacement therapy (GHRT) is effective versus placebo in the improvement of Quality of Life in patients with adult growth hormone deficiency (AGHD) and mild traumatic brain injury (mTBI).
• OEF/OIF/OND Veteran
• Score of 18 or more on Combat Experiences sub-scale of Deployment Risk and Resilience Inventory-2 (DRRI-2)
• Age 21 - 55 years old
• One or more mTBI sustained during military service at least 12 months prior to the screening date, as noted via the CRAFT survey
• GH deficiency diagnosed by: macimorelin stimulation test (cut point 5.1 mcg/L) and IGF-I lab values have to be less than or equal to +1 SDS at baseline
• Score of 11 or more on QoL-AGHDA
• 4-week stability on any psychotropic medications
• 3-month stability on all other hormone treatments
• Able and willing to provide informed consent to participate in this study, and complete study protocol.